CY1107678T1 - Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα - Google Patents

Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα

Info

Publication number
CY1107678T1
CY1107678T1 CY20071100805T CY071100805T CY1107678T1 CY 1107678 T1 CY1107678 T1 CY 1107678T1 CY 20071100805 T CY20071100805 T CY 20071100805T CY 071100805 T CY071100805 T CY 071100805T CY 1107678 T1 CY1107678 T1 CY 1107678T1
Authority
CY
Cyprus
Prior art keywords
dna sequences
regulatory sequences
suppressive activity
provides
clarifying
Prior art date
Application number
CY20071100805T
Other languages
Greek (el)
English (en)
Inventor
Arie Pieter Otte
Arthur Leo Kruckeberg
Original Assignee
Chromagenics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01202581A external-priority patent/EP1273666A1/en
Application filed by Chromagenics B.V. filed Critical Chromagenics B.V.
Publication of CY1107678T1 publication Critical patent/CY1107678T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CY20071100805T 2001-07-04 2007-06-19 Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα CY1107678T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01202581A EP1273666A1 (en) 2001-07-04 2001-07-04 Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
US30319901P 2001-07-05 2001-07-05
EP05076209A EP1600510B1 (en) 2001-07-04 2002-06-14 DNA sequences having anti-repressor activity
US10/190,312 US7192741B2 (en) 2001-07-04 2002-07-05 DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences

Publications (1)

Publication Number Publication Date
CY1107678T1 true CY1107678T1 (el) 2013-04-18

Family

ID=47915807

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100805T CY1107678T1 (el) 2001-07-04 2007-06-19 Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα

Country Status (21)

Country Link
US (9) US7192741B2 (enExample)
EP (8) EP1600510B1 (enExample)
JP (3) JP4500044B2 (enExample)
KR (2) KR100942117B1 (enExample)
CN (1) CN1266282C (enExample)
AT (8) ATE466942T1 (enExample)
AU (3) AU2002314629B2 (enExample)
BR (1) BRPI0210771B8 (enExample)
CA (2) CA2812799C (enExample)
CY (1) CY1107678T1 (enExample)
DE (8) DE60237048D1 (enExample)
DK (8) DK1845162T3 (enExample)
ES (8) ES2285630T3 (enExample)
IL (4) IL159674A0 (enExample)
MX (1) MXPA03011801A (enExample)
NO (1) NO338477B1 (enExample)
NZ (1) NZ530218A (enExample)
PT (1) PT1600510E (enExample)
SG (1) SG143066A1 (enExample)
WO (1) WO2003004704A2 (enExample)
ZA (1) ZA200309599B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237048D1 (de) 2001-07-04 2010-08-26 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
WO2003106674A2 (en) 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
CA2489475C (en) 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK1573058T3 (da) 2002-12-18 2012-01-16 Chromagenics Bv Fremgangsmåde til forbedring af proteinproduktion
DK1572994T3 (da) 2002-12-20 2007-05-29 Chromagenics Bv Midler og fremgangsmåder til fremstilling af en protein gennem chromatinåbnere, som kan göre chromatin mere tilgængeligt for transkriptionsfaktorer
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
CN1863918B (zh) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
DE602005003369T2 (de) 2004-07-08 2009-03-05 Chromagenics B.V. Neue sequenz um die expression einer nukleinsäure zu erhöhen
ATE459720T1 (de) * 2004-08-18 2010-03-15 Bayer Cropscience Ag Pflanzen mit erhöhter plastidär aktivität der stärkephosphorylierenden r3-enzyme
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
NZ553700A (en) 2004-11-08 2010-09-30 Chromagenics Bv Selection of host cells expressing protein at high levels using a selectable marker with a non-optimal start codon
US20060195935A1 (en) * 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20100136616A1 (en) * 2004-11-08 2010-06-03 Chromagenics B.V. Selection of Host Cells Expressing Protein at High Levels
BRPI0517380A (pt) 2004-11-08 2008-10-07 Chromagenics Bv molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
KR100959456B1 (ko) * 2004-11-18 2010-05-25 고쿠리츠다이가쿠호진 히로시마다이가쿠 유전자 증폭에 의해 형성된 반복서열로부터, 발현이 억제된단백질을 발현시키는 방법, 키트, 및 형질전환체
EP1996705B1 (en) 2006-03-20 2011-08-31 ChromaGenics B.V. Expression augmenting dna fragments, use thereof, and methods for finding thereof
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
JP2010515435A (ja) * 2007-01-08 2010-05-13 ミリポア・コーポレイション 遺伝子増幅を不要とする高発現細胞株
CN102459607B (zh) 2009-06-15 2014-08-06 萨拉基尼克有限公司 新的严格的可选择的标志物
US8566596B2 (en) 2010-08-24 2013-10-22 Cisco Technology, Inc. Pre-association mechanism to provide detailed description of wireless services
CN103180443B (zh) 2010-09-01 2016-01-13 萨拉基尼克有限公司 用于增强基因表达的来自核糖体蛋白启动子的核酸片段
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
US10417380B1 (en) 2013-12-31 2019-09-17 Mckesson Corporation Systems and methods for determining and communicating a prescription benefit coverage denial to a prescriber
US10489552B2 (en) 2014-02-14 2019-11-26 Mckesson Corporation Systems and methods for determining and communicating patient incentive information to a prescriber
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
US10157262B1 (en) 2015-03-10 2018-12-18 Mckesson Corporation Systems and methods for determining patient financial responsibility for multiple prescription products
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
US11514137B1 (en) 2016-03-30 2022-11-29 Mckesson Corporation Alternative therapy identification system
US10999224B1 (en) 2017-02-01 2021-05-04 Mckesson Corporation Method and apparatus for parsing an electronic message and constructing multiple differently prioritized messages therefrom
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
US10862832B1 (en) 2018-07-24 2020-12-08 Mckesson Corporation Computing system and method for automatically reversing an action indicated by an electronic message
US11043437B2 (en) 2019-01-07 2021-06-22 Applied Materials, Inc. Transparent substrate with light blocking edge exclusion zone
US12525327B1 (en) 2019-06-26 2026-01-13 Mckesson Corporation Method, apparatus, and computer program product for providing real-time pricing information
US12469040B1 (en) 2019-06-26 2025-11-11 Mckesson Corporation Method, apparatus, and computer program product for providing real-time pricing information
US11636548B1 (en) 2019-06-26 2023-04-25 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
US11562437B1 (en) 2019-06-26 2023-01-24 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
US20230104317A1 (en) * 2020-01-31 2023-04-06 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods to Identify Genetic Silencers and Applications Thereof
US11610240B1 (en) 2020-02-17 2023-03-21 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
US12229833B1 (en) 2020-02-17 2025-02-18 Mckesson Corporation Method, apparatus, and computer program product for reformatting an electronic prescription transaction
US12229834B1 (en) 2020-02-17 2025-02-18 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
CN116462766A (zh) 2020-05-21 2023-07-21 美勒斯公司 用于生产ig样分子的方法和手段
US11587657B2 (en) 2020-09-04 2023-02-21 Mckesson Corporation Method, apparatus, and computer program product for performing an alternative evaluation procedure in response to an electronic message
US12367954B1 (en) 2021-01-08 2025-07-22 Mckesson Corporation Method, apparatus, and computer program product for estimating a target quantitative measure based upon historical electronic messages
US12518304B1 (en) 2021-01-26 2026-01-06 Mckesson Corporation Method, apparatus, and computer program product for estimating a target quantitative measure based upon historical electronic messages
CN113539357B (zh) * 2021-06-10 2024-04-30 阿里巴巴达摩院(杭州)科技有限公司 基因检测方法、模型训练方法、装置、设备及系统
US12706199B1 (en) 2021-10-01 2026-08-11 Mckesson Corporation Method, apparatus, and computer program product for using machine learning to generate an offset amount
US12197972B1 (en) 2022-03-28 2025-01-14 Mckesson Corporation Method, apparatus, and computer program product for generating alternative evaluation messages

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US719271A (en) * 1902-01-13 1903-01-27 Solomon P Smith Furnace.
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5972605A (en) * 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
KR19980703267A (ko) * 1995-03-24 1998-10-15 요시히코시오노 유전자발현 억제에 관련된 ｄｎａ분자 및 신규 단백질
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6037525A (en) * 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO2000005393A2 (en) 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
IL141371A0 (en) * 1998-08-14 2002-03-10 Stichting Tech Wetenschapp Method of detecting a dna sequence, a dna sequence, a method of making a dna construct and the use thereof
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU1128400A (en) 1998-10-22 2000-05-08 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
NZ529329A (en) * 1999-08-25 2005-06-24 Immunex Corp Compositions and methods for improved cell culture
US6586205B1 (en) 2000-02-11 2003-07-01 Millennium Pharmaceuticals, Inc. 43239 a novel GPCR-like molecule and uses thereof
WO2001059117A2 (en) 2000-02-11 2001-08-16 Millennium Pharmaceuticals, Inc. Seven-transmembrane proteins/g-protein coupled receptors
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
EP1273666A1 (en) 2001-07-04 2003-01-08 Chromagenics B.V. Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
DE60237048D1 (de) 2001-07-04 2010-08-26 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
CA2489475C (en) * 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
WO2003106674A2 (en) 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
DK1573058T3 (da) 2002-12-18 2012-01-16 Chromagenics Bv Fremgangsmåde til forbedring af proteinproduktion
DK1572994T3 (da) 2002-12-20 2007-05-29 Chromagenics Bv Midler og fremgangsmåder til fremstilling af en protein gennem chromatinåbnere, som kan göre chromatin mere tilgængeligt for transkriptionsfaktorer

Also Published As

Publication number Publication date
DK1829972T3 (da) 2010-09-13
US20070026499A1 (en) 2007-02-01
NO20040011L (no) 2004-03-03
CN1524128A (zh) 2004-08-25
DE60236334D1 (de) 2010-06-17
EP1829972A3 (en) 2007-10-24
DK1842919T3 (da) 2010-08-16
EP1806407B1 (en) 2010-05-05
NZ530218A (en) 2005-09-30
ATE466944T1 (de) 2010-05-15
US20070031934A1 (en) 2007-02-08
DE60236332D1 (de) 2010-06-17
CN1266282C (zh) 2006-07-26
ES2344071T3 (es) 2010-08-17
CA2812799A1 (en) 2003-01-16
DE60219221D1 (de) 2007-05-10
ZA200309599B (en) 2006-05-31
US7662591B2 (en) 2010-02-16
AU2007234619B2 (en) 2011-06-02
EP1808488A2 (en) 2007-07-18
WO2003004704A3 (en) 2003-10-16
EP1829972A2 (en) 2007-09-05
JP4500044B2 (ja) 2010-07-14
IL193374A (en) 2010-12-30
CA2450020C (en) 2013-08-13
PT1600510E (pt) 2007-06-25
ATE466942T1 (de) 2010-05-15
JP2010131025A (ja) 2010-06-17
AU2011202193B2 (en) 2011-09-29
MXPA03011801A (es) 2005-03-07
IL159674A0 (en) 2004-06-20
DK1404872T3 (da) 2007-02-19
JP5014444B2 (ja) 2012-08-29
IL193373A (en) 2010-12-30
ES2344073T3 (es) 2010-08-17
US20070031933A1 (en) 2007-02-08
EP1806407A2 (en) 2007-07-11
DE60215502D1 (de) 2006-11-30
ATE467682T1 (de) 2010-05-15
DE60236379D1 (de) 2010-06-24
DE60236331D1 (de) 2010-06-17
EP1829972B1 (en) 2010-05-12
ES2344070T3 (es) 2010-08-17
US7192741B2 (en) 2007-03-20
US7655441B2 (en) 2010-02-02
EP1845162A1 (en) 2007-10-17
US7749733B2 (en) 2010-07-06
BRPI0210771B1 (pt) 2015-12-22
DK1808488T3 (da) 2010-10-18
US20070026498A1 (en) 2007-02-01
EP1829971B1 (en) 2010-05-05
US7736870B2 (en) 2010-06-15
WO2003004704A2 (en) 2003-01-16
EP1845162B1 (en) 2010-05-05
ATE466941T1 (de) 2010-05-15
ATE358183T1 (de) 2007-04-15
JP2004533262A (ja) 2004-11-04
KR20090037485A (ko) 2009-04-15
US20070031935A1 (en) 2007-02-08
JP5014443B2 (ja) 2012-08-29
US20070128717A1 (en) 2007-06-07
ES2344072T3 (es) 2010-08-17
AU2007234619A1 (en) 2007-12-13
DK1845162T3 (da) 2010-08-16
EP1806407A3 (en) 2008-06-04
EP1808488A3 (en) 2007-11-14
DE60236333D1 (de) 2010-06-17
US7659094B2 (en) 2010-02-09
NO338477B1 (no) 2016-08-22
AU2002314629B2 (en) 2007-08-30
ATE343004T1 (de) 2006-11-15
KR100942116B1 (ko) 2010-02-12
EP1842919B1 (en) 2010-05-05
AU2011202193A1 (en) 2011-06-02
ATE466943T1 (de) 2010-05-15
DK1806407T3 (da) 2010-08-16
DK1829971T3 (da) 2010-08-16
EP1808488B1 (en) 2010-07-14
EP1829971A3 (en) 2008-06-04
EP1600510A3 (en) 2006-02-22
DK1600510T3 (da) 2007-06-25
JP2010131024A (ja) 2010-06-17
ES2285630T3 (es) 2007-11-16
HK1068652A1 (en) 2005-04-29
US7736868B2 (en) 2010-06-15
US20030199468A1 (en) 2003-10-23
US7736869B2 (en) 2010-06-15
DE60215502T2 (de) 2007-08-30
BR0210771A (pt) 2004-07-13
ES2274045T3 (es) 2007-05-16
EP1600510A2 (en) 2005-11-30
DE60237048D1 (de) 2010-08-26
EP1600510B1 (en) 2007-03-28
EP1404872B1 (en) 2006-10-18
EP1842919A1 (en) 2007-10-10
CA2450020A1 (en) 2003-01-16
KR20090037960A (ko) 2009-04-16
CA2812799C (en) 2016-01-26
BRPI0210771B8 (pt) 2021-05-25
ES2348174T3 (es) 2010-11-30
US20070037256A1 (en) 2007-02-15
ATE474053T1 (de) 2010-07-15
DE60219221T2 (de) 2008-01-03
ES2344074T3 (es) 2010-08-17
KR100942117B1 (ko) 2010-02-12
US7951586B2 (en) 2011-05-31
SG143066A1 (en) 2008-06-27
EP1404872A2 (en) 2004-04-07
US20070031936A1 (en) 2007-02-08
IL159674A (en) 2009-02-11
EP1829971A1 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
DK1842919T3 (da) DNA-sekvenser med antirepressoraktivitet
CY1116149T1 (el) Αντισωματα anti-tnf, συνθεσεις, μεθοδοι και χρησεις αυτων
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
CY1118901T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
CY1114397T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν βακτηρια τα οποια μειωνουν οξαλικα
DE602004024909D1 (de) Platinkomplexe zur behandlung von tumoren
CY1109221T1 (el) Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
ATE390485T1 (de) Irak-4 zusammensetzungen und deren verwendungen
CY1110418T1 (el) Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE374834T1 (de) Methoden zur identifizierung evolutionär signifikanter änderungen in polynukleotid- und polypeptidsequenzen in domestizierten pflanzen und tieren
ATE476185T1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
CY1110755T1 (el) Αντι-διπλα αντισωματα ιντεγκρινης, συνθεσεις, μεθοδοι και χρησεις